{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:47:50Z","timestamp":1786978070258,"version":"build-2736575974"},"reference-count":40,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009032","name":"Pfizer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) is a relapsing, debilitating blood cancer which remains incurable despite advances in treatments. Patients typically receive multiple lines of treatment, to which they become refractory, thereby limiting treatment options. B\u2010cell maturation antigen (BCMA) bispecific antibodies (BsAbs) represent a novel modality of treatment that has significant efficacy for relapsed or refractory patients.<\/jats:p>\n                    <jats:p>The objective was to develop consensus statements for the effective implementation of BCMA BsAbs for relapsed or refractory MM patients within the National Health Service (NHS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The process employed a modified Delphi methodology. In March 2023, a literature review on the topic of novel treatments for MM was performed using the PubMed database.<\/jats:p>\n                    <jats:p>The process employed a modified Delphi methodology. Following a literature review, a steering group of eight expert clinicians identified and agreed on five main topics of focus and 44 statements. These were then developed into an online survey which was distributed to healthcare professionals working in Levels 1, 2 and 3 haematology centres in the United Kingdom. Results were then shared with the expert panel to determine conclusions. The threshold for consensus agreement was set at 75%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 60 responses were received from all three centre levels. There was representation from all targeted centres. Consensus was achieved in 42 statements (95%) across three broad areas: the patient profile, initiation and step\u2010up dosing, monitoring and ongoing care, the role of multidisciplinary team and service designs for optimal management, consensus was not achieved for two statements. Given the level of agreement and that the stopping criteria were met, it was decided not to undertake further Delphi rounds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This consensus provides a framework to support the effective introduction of novel treatments for MM in the NHS. The results were used to inform a checklist for use within haematology services when considering the provision of MM care specific to BCMA BsAbs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jha2.1038","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T06:25:21Z","timestamp":1729837521000},"page":"1133-1143","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The UK consensus supporting effective introduction of novel treatments for multiple myeloma in the National Health Service"],"prefix":"10.1002","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6553-4618","authenticated-orcid":false,"given":"Rakesh","family":"Popat","sequence":"first","affiliation":[{"name":"Haematology University College London Hospitals NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2206-4796","authenticated-orcid":false,"given":"Supratik","family":"Basu","sequence":"additional","affiliation":[{"name":"University of Wolverhampton The Royal Wolverhampton NHS Trust  Wolverhampton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Henshaw","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology Nottingham University Hospitals NHS Trust  Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4708-8092","authenticated-orcid":false,"given":"Kamaraj","family":"Karunanithi","sequence":"additional","affiliation":[{"name":"Clinical Haematology University Hospitals of North Midlands NHS Trust  Stoke\u2010on\u2010Trent UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3385-3707","authenticated-orcid":false,"given":"Karthik","family":"Ramasamy","sequence":"additional","affiliation":[{"name":"Oxford University Hospitals NHS Trust, Radcliffe Department of Medicine Oxford University  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7834-1938","authenticated-orcid":false,"given":"Inderjit","family":"Singh","sequence":"additional","affiliation":[{"name":"Queen Elizabeth Hospital University Hospitals Birmingham NHS Foundation Trust  Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6836-8555","authenticated-orcid":false,"given":"Anish","family":"Tailor","sequence":"additional","affiliation":[{"name":"Haematology University College London Hospitals NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2548-4502","authenticated-orcid":false,"given":"Ian","family":"Walker","sequence":"additional","affiliation":[{"name":"Triducive Partners Limited  St Albans UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Warren","sequence":"additional","affiliation":[{"name":"Triducive Partners Limited  St Albans UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noreen","family":"Ali","sequence":"additional","affiliation":[{"name":"Pfizer Limited  Tadworth UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1717-0412","authenticated-orcid":false,"given":"Charles","family":"Duffield","sequence":"additional","affiliation":[{"name":"Pfizer Limited  Tadworth UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[{"name":"Leeds Institute of Clinical Trial research &amp; Leeds Cancer Centre Leeds Teaching Hospitals NHS Trust  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205154"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/MCO2.146"},{"key":"e_1_2_13_5_1","unstructured":"National Institute for Health and Care Excellence.Multiple myeloma: prevalence.2022.https:\/\/cks.nice.org.uk\/topics\/multiple\u2010myeloma\/background\u2010information\/prevalence\/"},{"key":"e_1_2_13_6_1","unstructured":"Cancer Research UK.Myeloma statistics. Accessed Jan 2024.https:\/\/www.cancerresearchuk.org\/health\u2010professional\/cancer\u2010statistics\/statistics\u2010by\u2010cancer\u2010type\/myeloma"},{"key":"e_1_2_13_7_1","unstructured":"National Institute for Health and Care Excellence.Multiple myeloma: prognosis.2022.https:\/\/cks.nice.org.uk\/topics\/multiple\u2010myeloma\/background\u2010information\/prognosis\/"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01531-2"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.11.008"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34134"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184701"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061819"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0734-z"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/BLCTT.S327016"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S240886"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00159-6"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009435"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162440"},{"key":"e_1_2_13_20_1","unstructured":"Talquetamab summary of product characteristics.https:\/\/www.medicines.org.uk\/emc\/product\/15136\/smpc"},{"key":"e_1_2_13_21_1","unstructured":"Glofitamab summary of product characteristics.https:\/\/www.medicines.org.uk\/emc\/product\/15176\/smpc"},{"key":"e_1_2_13_22_1","unstructured":"Epcoritamab summary of product characteristics.https:\/\/www.medicines.org.uk\/emc\/product\/15187\/smpc"},{"key":"e_1_2_13_23_1","unstructured":"Blinatumomab summary of product characteristics.https:\/\/www.medicines.org.uk\/emc\/product\/5064\/smpc"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.12.002"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010020\u201000359\u20102"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/edbk_432204"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells7100155"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00043-3"},{"key":"e_1_2_13_29_1","unstructured":"UK Department of Health.Improving outcomes: a strategy for cancer.2011."},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7048"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02154-5"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7520"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010024\u201001003\u2010z"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174228"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-023-03579-x"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01016-0"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010023\u201000879\u20107"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010539"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1179\/102453309X12583347113492"},{"key":"e_1_2_13_40_1","unstructured":"NHS Scotland.Clinical guidelines for immunoglobulin use \u2013 third edition update.2021."},{"key":"e_1_2_13_41_1","unstructured":"NHS England.Clinical Commissioning Policy for the use of therapeutic immunoglobulin (Ig) England (2024) Commissioning position.2024."}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.1038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T07:50:13Z","timestamp":1734335413000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.1038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1002\/jha2.1038"],"URL":"https:\/\/doi.org\/10.1002\/jha2.1038","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]},"assertion":[{"value":"2024-07-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}